SARS-CoV-2-IN-13
Modify Date: 2025-08-25 09:06:32
SARS-CoV-2-IN-13 structure
|
Common Name | SARS-CoV-2-IN-13 | ||
|---|---|---|---|---|
| CAS Number | 56961-10-5 | Molecular Weight | 327.12 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C13H8Cl2N2O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SARS-CoV-2-IN-13SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally[1]. |
| Name | SARS-CoV-2-IN-13 |
|---|
| Description | SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally[1]. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C13H8Cl2N2O4 |
|---|---|
| Molecular Weight | 327.12 |
| InChIKey | FKLGWJUBUPDJJI-UHFFFAOYSA-N |
| SMILES | O=C(Nc1ccc([N+](=O)[O-])c(Cl)c1)c1cc(Cl)ccc1O |